JP2009533465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533465A5 JP2009533465A5 JP2009505564A JP2009505564A JP2009533465A5 JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5 JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- dvl
- item
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 229920001184 polypeptide Polymers 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 102000013814 Wnt Human genes 0.000 claims description 6
- 108050003627 Wnt Proteins 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 101150108602 DVL1 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79067306P | 2006-04-10 | 2006-04-10 | |
| US60/790,673 | 2006-04-10 | ||
| PCT/US2007/066267 WO2007121147A2 (en) | 2006-04-10 | 2007-04-09 | Disheveled pdz modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533465A JP2009533465A (ja) | 2009-09-17 |
| JP2009533465A5 true JP2009533465A5 (enExample) | 2010-05-20 |
| JP5290148B2 JP5290148B2 (ja) | 2013-09-18 |
Family
ID=38537937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505564A Expired - Fee Related JP5290148B2 (ja) | 2006-04-10 | 2007-04-09 | Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7695928B2 (enExample) |
| EP (2) | EP2002259B1 (enExample) |
| JP (1) | JP5290148B2 (enExample) |
| CN (2) | CN101467039B (enExample) |
| AU (1) | AU2007238186B2 (enExample) |
| CA (1) | CA2648322C (enExample) |
| ES (2) | ES2385261T3 (enExample) |
| WO (1) | WO2007121147A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI494319B (zh) * | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| KR101278073B1 (ko) * | 2008-08-04 | 2013-06-24 | 연세대학교 산학협력단 | Ｉｄｂｆ의 신규 용도 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| EP2812350B1 (en) | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
| GB201220901D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| GB201220891D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating breast cancers |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| US9520180B1 (en) | 2014-03-11 | 2016-12-13 | Hypres, Inc. | System and method for cryogenic hybrid technology computing and memory |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8319174D0 (en) * | 1983-07-15 | 1983-08-17 | Erba Farmitalia | Biologically active heptapeptides |
| GB8430255D0 (en) * | 1984-11-30 | 1985-01-09 | Erba Farmitalia | Biologically active oligopeptides |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE189526T1 (de) | 1988-10-28 | 2000-02-15 | Genentech Inc | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5688936A (en) * | 1992-06-11 | 1997-11-18 | The Regents Of The University Of California | Vesicle membrane transport proteins |
| ES2151541T3 (es) | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| BR9509201A (pt) | 1994-09-09 | 1997-12-30 | Takeda Chemical Industries Ltd | Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada |
| EP0831787B1 (en) | 1995-06-07 | 2001-08-22 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| EP1100890A2 (en) | 1998-07-27 | 2001-05-23 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
| WO2002090544A2 (en) * | 2001-05-04 | 2002-11-14 | Hybrigenics | Protein-protein interactions in adipocyte cells (3) |
| EP1493028A4 (en) * | 2001-07-06 | 2006-06-14 | Genentech Inc | PHAGEN DISPLAY PRESENTED LIGANDS OF THE PDZ DOMAIN |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| CA2501235A1 (en) | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methods for treating cancer by inhibiting wnt signaling |
| EP1781609A4 (en) * | 2004-07-01 | 2009-07-29 | Univ California | INHIBITION OF A PDZ DOMAIN INTERACTION BY SMALL MOLECULES |
-
2007
- 2007-04-09 US US11/733,146 patent/US7695928B2/en not_active Expired - Fee Related
- 2007-04-09 AU AU2007238186A patent/AU2007238186B2/en not_active Ceased
- 2007-04-09 CN CN2007800216108A patent/CN101467039B/zh not_active Expired - Fee Related
- 2007-04-09 ES ES07760350T patent/ES2385261T3/es active Active
- 2007-04-09 WO PCT/US2007/066267 patent/WO2007121147A2/en not_active Ceased
- 2007-04-09 EP EP07760350A patent/EP2002259B1/en active Active
- 2007-04-09 CA CA2648322A patent/CA2648322C/en not_active Expired - Fee Related
- 2007-04-09 ES ES11154863.2T patent/ES2487637T3/es active Active
- 2007-04-09 CN CN201310261484.0A patent/CN103351425B/zh not_active Expired - Fee Related
- 2007-04-09 EP EP11154863.2A patent/EP2343551B1/en not_active Not-in-force
- 2007-04-09 JP JP2009505564A patent/JP5290148B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-29 US US12/696,875 patent/US7977064B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533465A5 (enExample) | ||
| Adihou et al. | A protein tertiary structure mimetic modulator of the Hippo signalling pathway | |
| Chevet et al. | Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development | |
| Jenssen et al. | Serum stability of peptides | |
| Loerch et al. | Unmasking the U2AF homology motif family: a bona fide protein–protein interaction motif in disguise | |
| EA200800536A1 (ru) | Тканезащитные пептиды и их применения | |
| Li et al. | ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression | |
| US20100216716A1 (en) | Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway | |
| Hoshijima et al. | Roles of heterotypic CCN2/CTGF–CCN3/NOV and homotypic CCN2–CCN2 interactions in expression of the differentiated phenotype of chondrocytes | |
| JP2010522541A5 (enExample) | ||
| AU2025204787A1 (en) | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | |
| JP2018538356A5 (enExample) | ||
| US8183339B1 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| JP2023546561A (ja) | ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 | |
| JP2010528584A5 (enExample) | ||
| CA2357015A1 (en) | Agents for treating human illnesses based on .beta.-catenin, and the production and use thereof | |
| EP2268658A1 (en) | Peptides and aptamers thereof as specific modulators of mutant p53 function | |
| ATE253636T1 (de) | Mit smad wechselwirkende polypeptide und verwendungen davon | |
| Johansson et al. | Tetrapeptides as potent protease inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase) | |
| Denholt et al. | Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library | |
| JP2012512259A (ja) | クプレドキシンにより癌を予防するための組成物および方法 | |
| Puszko et al. | Urea moiety as amide bond mimetic in peptide-like inhibitors of VEGF-A165/NRP-1 complex | |
| Katritzky et al. | Microwave‐assisted solid‐phase peptide synthesis utilizing N‐Fmoc‐protected (α‐aminoacyl) benzotriazoles | |
| DE69925116D1 (de) | Neue, physiologisch aktive peptide und ihre verwendung. | |
| Khan et al. | Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability |